Annual EBIT:
$279.10M-$4.14B(-93.69%)Summary
- As of April 2, 2025, VRTX annual earnings before interest & taxes is $279.10 million, with the most recent change of -$4.14 billion (-93.69%) on December 31, 2024.
- During the last 3 years, VRTX annual EBIT has fallen by -$2.51 billion (-90.00%).
- VRTX annual EBIT is now -93.69% below its all-time high of $4.42 billion, reached on December 31, 2023.
Performance
VRTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT:
$1.14B-$92.30M(-7.49%)Summary
- As of April 2, 2025, VRTX quarterly earnings before interest & taxes is $1.14 billion, with the most recent change of -$92.30 million (-7.49%) on December 31, 2024.
- Over the past year, VRTX quarterly EBIT has stayed the same.
- VRTX quarterly EBIT is now -11.65% below its all-time high of $1.29 billion, reached on March 31, 2024.
Performance
VRTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT:
$279.10M-$18.90M(-6.34%)Summary
- As of April 2, 2025, VRTX TTM earnings before interest & taxes is $279.10 million, with the most recent change of -$18.90 million (-6.34%) on December 31, 2024.
- Over the past year, VRTX TTM EBIT has stayed the same.
- VRTX TTM EBIT is now -94.20% below its all-time high of $4.81 billion, reached on March 31, 2024.
Performance
VRTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
VRTX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -93.7% | 0.0% | 0.0% |
| 3 y3 years | -90.0% | -4.3% | -93.2% |
| 5 y5 years | -80.8% | -4.3% | -93.2% |
VRTX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -93.7% | at low | -11.7% | +133.7% | -94.2% | +8.8% |
| 5 y | 5-year | -93.7% | at low | -11.7% | +133.7% | -94.2% | +8.8% |
| alltime | all time | -93.7% | +137.9% | -11.7% | +133.7% | -94.2% | +137.8% |
Vertex Pharmaceuticals Incorporated EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $279.10M(-93.7%) | $1.14B(-7.5%) | $279.10M(-6.3%) |
| Sep 2024 | - | $1.23B(-136.4%) | $298.00M(+16.2%) |
| Jun 2024 | - | -$3.38B(-362.2%) | $256.50M(-94.7%) |
| Mar 2024 | - | $1.29B(+11.3%) | $4.81B(+8.7%) |
| Dec 2023 | $4.42B(+3.2%) | $1.16B(-2.7%) | $4.42B(+1.6%) |
| Sep 2023 | - | $1.19B(+1.5%) | $4.35B(0.0%) |
| Jun 2023 | - | $1.17B(+29.9%) | $4.35B(+3.2%) |
| Mar 2023 | - | $902.90M(-17.0%) | $4.22B(-1.6%) |
| Dec 2022 | $4.29B(+53.6%) | $1.09B(-8.5%) | $4.29B(+5.0%) |
| Sep 2022 | - | $1.19B(+14.5%) | $4.08B(+2.3%) |
| Jun 2022 | - | $1.04B(+7.1%) | $3.99B(+36.5%) |
| Mar 2022 | - | $969.70M(+9.4%) | $2.92B(+4.8%) |
| Dec 2021 | $2.79B(-12.1%) | $886.00M(-19.3%) | $2.79B(-0.7%) |
| Sep 2021 | - | $1.10B(-3925.8%) | $2.81B(+13.7%) |
| Jun 2021 | - | -$28.70M(-103.4%) | $2.47B(-26.0%) |
| Mar 2021 | - | $836.60M(-7.6%) | $3.34B(+5.2%) |
| Dec 2020 | $3.18B(+118.5%) | $905.06M(+19.1%) | $3.18B(+7.2%) |
| Sep 2020 | - | $759.73M(-9.4%) | $2.96B(+29.5%) |
| Jun 2020 | - | $838.64M(+24.9%) | $2.29B(+27.7%) |
| Mar 2020 | - | $671.67M(-2.8%) | $1.79B(+23.2%) |
| Dec 2019 | $1.45B(+116.1%) | $691.18M(+711.1%) | $1.45B(+78.7%) |
| Sep 2019 | - | $85.21M(-75.1%) | $813.46M(-7.9%) |
| Jun 2019 | - | $341.98M(+2.1%) | $883.45M(+13.8%) |
| Mar 2019 | - | $335.03M(+553.8%) | $776.22M(+15.4%) |
| Dec 2018 | $672.71M(+1154.8%) | $51.24M(-67.0%) | $672.71M(-11.3%) |
| Sep 2018 | - | $155.20M(-33.9%) | $758.21M(+280.2%) |
| Jun 2018 | - | $234.75M(+1.4%) | $199.41M(+1243.9%) |
| Mar 2018 | - | $231.53M(+69.3%) | $14.84M(-72.3%) |
| Dec 2017 | $53.61M(+281.1%) | $136.74M(-133.9%) | $53.61M(-226.5%) |
| Sep 2017 | - | -$403.60M(-904.5%) | -$42.38M(-112.4%) |
| Jun 2017 | - | $50.17M(-81.4%) | $342.32M(+16.3%) |
| Mar 2017 | - | $270.30M(+563.4%) | $294.28M(+1992.2%) |
| Dec 2016 | $14.07M(-103.0%) | $40.74M(-315.7%) | $14.07M(-117.1%) |
| Sep 2016 | - | -$18.89M(-985.4%) | -$82.07M(-39.0%) |
| Jun 2016 | - | $2.13M(-121.5%) | -$134.53M(-56.1%) |
| Mar 2016 | - | -$9.92M(-82.1%) | -$306.42M(-35.3%) |
| Dec 2015 | -$473.59M(-28.5%) | -$55.39M(-22.4%) | -$473.59M(-17.7%) |
| Sep 2015 | - | -$71.35M(-58.0%) | -$575.62M(-11.5%) |
| Jun 2015 | - | -$169.75M(-4.1%) | -$650.46M(+4.3%) |
| Mar 2015 | - | -$177.10M(+12.5%) | -$623.52M(-5.8%) |
| Dec 2014 | -$662.01M(+9.8%) | -$157.42M(+7.7%) | -$662.01M(+29.5%) |
| Sep 2014 | - | -$146.19M(+2.4%) | -$511.35M(+5.7%) |
| Jun 2014 | - | -$142.81M(-33.8%) | -$483.96M(+21.6%) |
| Mar 2014 | - | -$215.59M(+3093.5%) | -$398.11M(-36.0%) |
| Dec 2013 | -$603.12M(-1382.2%) | -$6.75M(-94.3%) | -$621.99M(-4.3%) |
| Sep 2013 | - | -$118.81M(+108.6%) | -$649.66M(+22.3%) |
| Jun 2013 | - | -$56.96M(-87.0%) | -$531.23M(+9.7%) |
| Mar 2013 | - | -$439.48M(+1176.7%) | -$484.45M(-1130.0%) |
| Dec 2012 | $47.04M(-52.1%) | -$34.42M(+9079.2%) | $47.03M(-84.5%) |
| Sep 2012 | - | -$375.00K(-96.3%) | $303.92M(-40.6%) |
| Jun 2012 | - | -$10.18M(-111.1%) | $511.96M(+44.5%) |
| Mar 2012 | - | $92.01M(-58.6%) | $354.23M(+261.0%) |
| Dec 2011 | $98.13M(-113.3%) | $222.46M(+7.1%) | $98.13M(-133.0%) |
| Sep 2011 | - | $207.67M(-223.7%) | -$297.04M(-58.1%) |
| Jun 2011 | - | -$167.91M(+2.3%) | -$709.72M(-3.8%) |
| Mar 2011 | - | -$164.09M(-5.0%) | -$738.13M(+0.6%) |
| Dec 2010 | -$735.35M(+16.9%) | -$172.71M(-15.8%) | -$733.54M(-0.1%) |
| Sep 2010 | - | -$205.01M(+4.4%) | -$734.60M(+8.5%) |
| Jun 2010 | - | -$196.32M(+23.1%) | -$677.05M(+6.3%) |
| Mar 2010 | - | -$159.50M(-8.2%) | -$636.79M(+1.2%) |
| Dec 2009 | -$628.99M(+37.2%) | -$173.77M(+17.8%) | -$628.99M(+5.6%) |
| Sep 2009 | - | -$147.46M(-5.5%) | -$595.44M(+3.1%) |
| Jun 2009 | - | -$156.06M(+2.9%) | -$577.72M(+12.8%) |
| Mar 2009 | - | -$151.70M(+8.2%) | -$511.98M(+11.7%) |
| Dec 2008 | -$458.38M(+11.1%) | -$140.22M(+8.1%) | -$458.38M(+11.9%) |
| Sep 2008 | - | -$129.74M(+43.7%) | -$409.63M(+4.3%) |
| Jun 2008 | - | -$90.31M(-7.9%) | -$392.80M(-8.1%) |
| Mar 2008 | - | -$98.11M(+7.3%) | -$427.20M(+3.5%) |
| Dec 2007 | -$412.67M | -$91.47M(-19.0%) | -$412.67M(+16.2%) |
| Sep 2007 | - | -$112.91M(-9.5%) | -$355.11M(+17.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | -$124.71M(+49.2%) | -$302.91M(+17.9%) |
| Mar 2007 | - | -$83.57M(+146.5%) | -$256.97M(+14.0%) |
| Dec 2006 | -$225.39M(+59.0%) | -$33.91M(-44.2%) | -$225.39M(+6.6%) |
| Sep 2006 | - | -$60.71M(-22.9%) | -$211.48M(+10.3%) |
| Jun 2006 | - | -$78.78M(+51.5%) | -$191.68M(+25.1%) |
| Mar 2006 | - | -$51.99M(+160.0%) | -$153.24M(+8.1%) |
| Dec 2005 | -$141.74M(+3.3%) | -$20.00M(-51.1%) | -$141.74M(-5.4%) |
| Sep 2005 | - | -$40.92M(+1.4%) | -$149.82M(+4.8%) |
| Jun 2005 | - | -$40.34M(-0.4%) | -$142.93M(-0.0%) |
| Mar 2005 | - | -$40.49M(+44.2%) | -$142.99M(+4.2%) |
| Dec 2004 | -$137.23M(-20.5%) | -$28.08M(-17.5%) | -$137.23M(-7.0%) |
| Sep 2004 | - | -$34.03M(-15.8%) | -$147.56M(-6.4%) |
| Jun 2004 | - | -$40.40M(+16.3%) | -$157.57M(-23.6%) |
| Mar 2004 | - | -$34.73M(-9.6%) | -$206.18M(+35.4%) |
| Dec 2003 | -$172.70M(+16.7%) | -$38.41M(-12.8%) | -$152.24M(-13.4%) |
| Sep 2003 | - | -$44.04M(-50.5%) | -$175.86M(+4.9%) |
| Jun 2003 | - | -$89.01M(-563.4%) | -$167.67M(+63.3%) |
| Mar 2003 | - | $19.21M(-131.0%) | -$102.69M(-30.6%) |
| Dec 2002 | -$147.96M(+28.5%) | -$62.02M(+73.0%) | -$147.96M(+1.3%) |
| Sep 2002 | - | -$35.85M(+49.2%) | -$146.06M(+11.8%) |
| Jun 2002 | - | -$24.03M(-7.8%) | -$130.61M(+5.3%) |
| Mar 2002 | - | -$26.06M(-56.6%) | -$124.03M(+9.4%) |
| Dec 2001 | -$115.10M(+207.4%) | -$60.12M(+194.7%) | -$113.36M(+70.7%) |
| Sep 2001 | - | -$20.40M(+16.9%) | -$66.41M(+8.5%) |
| Jun 2001 | - | -$17.45M(+13.3%) | -$61.18M(+78.5%) |
| Mar 2001 | - | -$15.39M(+17.0%) | -$34.28M(-6.9%) |
| Dec 2000 | -$37.44M(-26.0%) | -$13.16M(-13.2%) | -$36.80M(+51.8%) |
| Sep 2000 | - | -$15.17M(-260.5%) | -$24.25M(-4.4%) |
| Jun 2000 | - | $9.45M(-152.7%) | -$25.37M(-47.1%) |
| Mar 2000 | - | -$17.92M(+2867.1%) | -$48.00M(-4.9%) |
| Dec 1999 | -$50.60M(+5.9%) | -$604.00K(-96.3%) | -$50.48M(-34.9%) |
| Sep 1999 | - | -$16.30M(+23.7%) | -$77.58M(+22.4%) |
| Jun 1999 | - | -$13.18M(-35.4%) | -$63.38M(+6.0%) |
| Mar 1999 | - | -$20.40M(-26.4%) | -$59.80M(+15.7%) |
| Dec 1998 | -$47.80M(+149.0%) | -$27.70M(+1219.0%) | -$51.70M(+69.5%) |
| Sep 1998 | - | -$2.10M(-78.1%) | -$30.50M(-10.6%) |
| Jun 1998 | - | -$9.60M(-22.0%) | -$34.10M(+32.7%) |
| Mar 1998 | - | -$12.30M(+89.2%) | -$25.70M(+35.3%) |
| Dec 1997 | -$19.20M(-51.4%) | -$6.50M(+14.0%) | -$19.00M(-31.4%) |
| Sep 1997 | - | -$5.70M(+375.0%) | -$27.70M(-5.8%) |
| Jun 1997 | - | -$1.20M(-78.6%) | -$29.40M(-19.5%) |
| Mar 1997 | - | -$5.60M(-63.2%) | -$36.50M(-7.6%) |
| Dec 1996 | -$39.50M(+49.1%) | -$15.20M(+105.4%) | -$39.50M(+48.5%) |
| Sep 1996 | - | -$7.40M(-10.8%) | -$26.60M(-2.2%) |
| Jun 1996 | - | -$8.30M(-3.5%) | -$27.20M(-6.8%) |
| Mar 1996 | - | -$8.60M(+273.9%) | -$29.20M(+10.2%) |
| Dec 1995 | -$26.50M(+28.0%) | -$2.30M(-71.3%) | -$26.50M(-18.7%) |
| Sep 1995 | - | -$8.00M(-22.3%) | -$32.60M(+14.8%) |
| Jun 1995 | - | -$10.30M(+74.6%) | -$28.40M(+20.9%) |
| Mar 1995 | - | -$5.90M(-29.8%) | -$23.50M(+13.0%) |
| Dec 1994 | -$20.70M(-1825.0%) | -$8.40M(+121.1%) | -$20.80M(+447.4%) |
| Sep 1994 | - | -$3.80M(-29.6%) | -$3.80M(+31.0%) |
| Jun 1994 | - | -$5.40M(+68.8%) | -$2.90M(-293.3%) |
| Mar 1994 | - | -$3.20M(-137.2%) | $1.50M(+25.0%) |
| Dec 1993 | $1.20M(-112.0%) | $8.60M(-396.6%) | $1.20M(-111.7%) |
| Sep 1993 | - | -$2.90M(+190.0%) | -$10.30M(+3.0%) |
| Jun 1993 | - | -$1.00M(-71.4%) | -$10.00M(-11.5%) |
| Mar 1993 | - | -$3.50M(+20.7%) | -$11.30M(+14.1%) |
| Dec 1992 | -$10.00M(+78.6%) | -$2.90M(+11.5%) | -$9.90M(+13.8%) |
| Sep 1992 | - | -$2.60M(+13.0%) | -$8.70M(+16.0%) |
| Jun 1992 | - | -$2.30M(+9.5%) | -$7.50M(+15.4%) |
| Mar 1992 | - | -$2.10M(+23.5%) | -$6.50M(+80.6%) |
| Dec 1991 | -$5.60M(+36.6%) | -$1.70M(+21.4%) | -$3.60M(-53.2%) |
| Sep 1991 | - | -$1.40M(+7.7%) | -$7.70M(+35.1%) |
| Jun 1991 | - | -$1.30M(-262.5%) | -$5.70M(+50.0%) |
| Mar 1991 | - | $800.00K(-113.8%) | -$3.80M(-7.3%) |
| Dec 1990 | -$4.10M | -$5.80M(-1066.7%) | -$4.10M(-341.2%) |
| Sep 1990 | - | $600.00K(0.0%) | $1.70M(+54.5%) |
| Jun 1990 | - | $600.00K(+20.0%) | $1.10M(+120.0%) |
| Mar 1990 | - | $500.00K | $500.00K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual earnings before interest & taxes?
- What is the all time high annual EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual EBIT year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM EBIT year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual earnings before interest & taxes?
The current annual EBIT of VRTX is $279.10M
What is the all time high annual EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual earnings before interest & taxes is $4.42B
What is Vertex Pharmaceuticals Incorporated annual EBIT year-on-year change?
Over the past year, VRTX annual earnings before interest & taxes has changed by -$4.14B (-93.69%)
What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
The current quarterly EBIT of VRTX is $1.14B
What is the all time high quarterly EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly earnings before interest & taxes is $1.29B
What is Vertex Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
Over the past year, VRTX quarterly earnings before interest & taxes has changed by $0.00 (0.00%)
What is Vertex Pharmaceuticals Incorporated TTM earnings before interest & taxes?
The current TTM EBIT of VRTX is $279.10M
What is the all time high TTM EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM earnings before interest & taxes is $4.81B
What is Vertex Pharmaceuticals Incorporated TTM EBIT year-on-year change?
Over the past year, VRTX TTM earnings before interest & taxes has changed by $0.00 (0.00%)